Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Induction Chemotherapy for Locally Advanced SCC of the EAC
NCT07370337Phase 2Recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Squamous cell carcinoma of the external auditory canal, sponsored by Eye and ENT Hospital of Fudan University. Started May 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
Squamous cell carcinoma of the external auditory canal
Beyond the preview
Go deeper on NCT07370337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07370337.